"Evaluation of the safety and effect of treatment with intranasal NeuroEPO in patients with type 2 Spinocerebellar Ataxia"
Latest Information Update: 30 May 2022
At a glance
- Drugs Recombinant erythropoietin (Primary)
- Indications Spinocerebellar ataxias
- Focus Therapeutic Use
- Acronyms NeuroEPO-Ataxia
Most Recent Events
- 23 May 2022 Results published in the Movement Disorders
- 21 Jan 2016 New trial record